Lv4
630 积分 2021-10-13 加入
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study
11小时前
求助中
Analysis of bladder cancer therapeutic drug clinical trials in mainland China and globally
9天前
已完结
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
12天前
已完结
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
12天前
已完结
Shaping CDK4/6 inhibitor resistance: BRCA2 germline alterations bias towards RB1 inactivation
12天前
已完结
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
12天前
已完结
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone Metastases
26天前
已完结
Tumor microenvironment promotes breast cancer chemoresistance
1个月前
已完结
Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2- metastatic breast cancer: clinical and molecular perspectives
1个月前
已完结
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
1个月前
已完结
皖公网安备34019202002308
